Home›Stocks›ELVN

ELVN — structural market context

Enliven Therapeutics, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 23. Each line shows the earlier value, the later value and their dates.

Price

Close $41.52 (Oct 23) vs $41.93 (Oct 22): −0.98%.

Volume

1.69× its 20-session average (1.4M) on Oct 23.

Includes pre- and post-market trading.

Short interest

Short interest 10.4M shares (settlement Sep 30) vs 8.6M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 1 day with fails, largest 1 shares on Sep 23.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 2 days with fails, largest 29K shares on Sep 10.

No new publication in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

ELVN events and their magnitude

Latest SEC filing in the event study

Form 4 · other · filed 2026-10-21 · View on sec.gov ↗

…

Open the Event Study →

ELVN short interest & days to cover

SHARES SHORT
10.4M
% OF FLOAT
22.1%
DAYS TO COVER
5.5
CHANGE VS PRIOR
+20.1%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (24d ago)

ELVN fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-23 · 31d1$48.19
2026-09-11 · 43d31$56.23
2026-09-10 · 44d29K$57.45

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

ELVN insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 13 sales

InsiderTypeSharesValueFiled
Hohl Benjamin · officer: CHIEF FINANCIAL OFFICERSale (S)6K$232K2026-10-21
Collins Helen Louise · officer: CHIEF MEDICAL OFFICERSale (S)5K$192K2026-10-21
Garland J. Scott · directorSale (S)13K$607K2026-10-05
Hohl Benjamin · officer: CHIEF FINANCIAL OFFICERSale (S)2K$111K2026-09-21
Hohl Benjamin · officer: CHIEF FINANCIAL OFFICERSale (S)289$15K2026-09-21

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

ELVN analyst ratings

FirmActionRatingPublished
H.C. WainwrightholdBuy2026-10-19
GuggenheimholdBuy2026-10-08
Morgan StanleyinitialiseOverweight2026-10-02
Morgan Stanleyprice_target—2026-10-02
Mizuho Securitiesprice_target—2026-08-18

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is ELVN's short interest?
As of the FINRA settlement date 2026-09-30, ELVN had 10.4M shares sold short — 22.1% of its float, with 5.5 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying ELVN?
In the last 12 months of SEC Form 4 filings, ELVN recorded 0 insider purchases and 13 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about ELVN?
The most recent action: H.C. Wainwright hold to Buy on 2026-10-19. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell ELVN?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with E

EAT · Brinker International, Inc.EDRY · EuroDry Ltd. Common SharesEFX · Equifax, IncorporatedEFXT · Enerflex Ltd.EIKN · Eikon Therapeutics, Inc.EL · The Estee Lauder Companies IncAll E →

ELVN: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.